Current HER2+ BC treatments comprise surgery, radiotherapy, and chemotherapy (anthracylines, taxanes, CTX, methotrexate, and 5-fluorouracil), coadministered with various anti-HER2 compounds (trastuzumab, pertuzumab, drug-conjugated trastuzumab (ADCs), and tyrosine kinase inhibitors). The gene discussed is ERBB2; the disease is breast cancer.